{"entity":{"id":"stc-1010","kind":"drug","name":"STC-1010","aka":[],"tldr":"STC-1010 is an experimental off-the-shelf in vivo immunotherapy from stimulated, inactivated allogeneic cancer cell lines from Brenus Pharma, in phase 1 trials for unresectable locally advanced or metastatic pMMR/MSS colorectal cancer.","summary":"STC-1010 is an off-the-shelf in vivo immunotherapy from stimulated, inactivated allogeneic cancer cell lines (the company calls it an in vivo DC-engager) from Brenus Pharma. Made from selected allogeneic human cancer cell lines (Stimulated-Ghost-Cells); the company describes it as an in vivo DC-engager designed to make immunologically 'cold' tumours visible to immune cells. It is given with oral low-dose cyclophosphamide, with or without GM-CSF, alongside first-line chemotherapy. Its furthest stage is phase 1, for unresectable locally advanced or metastatic pMMR/MSS colorectal cancer. ClinicalTrials.gov registers it in one study linked below. Phase I/IIa BreAK CRC-001 (NCT06934538, registry PHASE1/PHASE2, recruiting); phase Ia dose-escalation data at ESMO 2026 (press release 23 Oct 2026). FDA accepted the IND in May 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Brenus Pharma: brenus-pharma.com","url":"https://www.brenus-pharma.com/science-innovation"},{"label":"Brenus Pharma: brenus-pharma.com","url":"https://www.brenus-pharma.com/articles/brenus-pharma-esmo-2026-stc-1010-phase-1a-results"},{"label":"Brenus Pharma: brenus-pharma.com","url":"https://www.brenus-pharma.com/articles/brenus-pharma-esmo-2026-stc-1010-phase-1a-results"},{"label":"Brenus Pharma: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06934538"},{"label":"ClinicalTrials.gov: trials of STC-1010","url":"https://clinicaltrials.gov/search?intr=STC-1010"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["brenus-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06934538"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"STC-1010","modality":"Off-the-shelf in vivo immunotherapy from stimulated, inactivated allogeneic cancer cell lines (the company calls it an in vivo DC-engager)","mechanism":"Made from selected allogeneic human cancer cell lines (Stimulated-Ghost-Cells); the company describes it as an in vivo DC-engager designed to make immunologically 'cold' tumours visible to immune cells. It is given with oral low-dose cyclophosphamide, with or without GM-CSF, alongside first-line chemotherapy.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/stc-1010/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"company":[{"id":"brenus-pharma","kind":"company","name":"Brenus Pharma","route":"/companies/brenus-pharma/"}],"trial":[{"id":"nct06934538","kind":"trial","name":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","route":"/trials/nct06934538/"}]}}